Skip to content

The Use of Synthetic Mesh in Contaminated and Infected Abdominal Wall Repairs. A Long-term Prospective Clinical Trial

The Use of Synthetic Mesh in Contaminated and Infected Abdominal Wall Repairs: Challenging the Dogma of an Absolute Contra-indication. A Long-term Prospective Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03702153
Enrollment
80
Registered
2018-10-10
Start date
2012-01-01
Completion date
2018-02-28
Last updated
2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Wall Defect, Abdominal Wall Fistula, Abdominal Wall Infection, Infection

Keywords

ventral hernia, mesh infection, enteric fistula, polypropylene mesh, synthetic mesh, abdominal wall reconstruction, complex hernia

Brief summary

Background: Abdominal wall reconstruction in patients presenting with enteric fistulas and mesh infection is challenging. There is a consensus that synthetic mesh must be avoided in infected operations. The alternatives to using synthetic mesh, such as component separation techniques and biologic mesh, present disappointing results with expressive wound infection and hernia recurrence rates. Methods: A prospective clinical trial designed to evaluate the short and the long-term outcomes of patients submitted to elective abdominal wall repair with synthetic mesh in the dirty-infected setting, and compared to a cohort of patients submitted to clean ventral hernia repairs.

Detailed description

We designed a prospective study, evaluating the short and the long-term outcomes of the surgical treatment of 40 consecutive patients presenting with an infected abdominal wall, compared to a cohort of 40 patients submitted to clean ventral hernia repairs. Patients were admitted between January 2012 and February 2015, and operated at the Hospital das Clinicas of the University of São Paulo School of Medicine, in Brazil. All patients included in the study group carried an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia. All the operations required in this group were classified as Class IV (dirty-infected), accordingly to the CDC Wound Classifications, as adopted by the European registry for abdominal wall hernias. The only inclusion criterion was the presence of an active chronic mesh infection. The infected abdominal wall (IM) group and the outcomes of the treatment were compared to a clean-control (CC) group of patients who underwent clean abdominal wall reconstructions, originally belonging to a prospective study of the tensiometry of the abdominal wall, and operated during the same period and in the same conditions. The exclusion criteria were: giant ventral hernias with a volume ratio higher than 25%, patients on immunosuppressive therapy or using corticosteroids, patients with hepatic cirrhosis and portal hypertension, Chron´s disease, acute postoperative mesh infection, chronic mesh infections following inguinal hernia repair and emergency operations.The data assessed included gender, age, body mass index (BMI), American Society of Anesthesiologists (ASA) score, comorbidities, smoking status, cancer history, the number of previous abdominal operations, the number of prior hernia operations, the presence of a recurrent incisional hernia and/or enteric fistula and the presentation of the mesh infection. Perioperative data included operative time, anesthesia time, associated procedures, the defect characteristics and the extension of the pre-aponeurotic dissection. Further analysis in the infected mesh (IM) group included the type and position of the infected mesh, the causes for the mesh infection and the microbiology of mesh explants. Patients were followed and operated at the Abdominal Wall and Hernia Repair Unit of the General Surgery and Trauma Discipline, and five surgeons of the team conducted the operations in both groups. Informed consents were presented to the patients in the IM group upon admission. Patients in the CC group signed informed consents to participate the study, during their post-operative follow-up visits. Surgical procedure The operations were performed through the previous surgical incision. Patients in the IM group had the infected mesh removed completely together with all the sutures, tacks or other foreign material. The surrounding fibrotic tissue and the existing sinus tracts were resected to perform a complete toilet of the abdominal wall. The abdominal cavity was entered in most of the patients, and associated or incidental procedures were made as required. After the removal of the infected mesh, or at the end of the abdominal cavity workup, all the surgical drapes, instruments and gloves were replaced. The size of the defect and the extension of the anterior abdominal wall dissection were estimated. The reconstruction of the midline was done as anatomically as possible, by repositioning of the muscles and primary closure of the aponeurosis. We did not use component separation techniques or transverse abdominal releases in any case. In some patients, a bilateral relaxing incision along the anterior rectus sheath was required to allow the re-approximation of the muscles in the midline. In all patients, a heavyweight macroporous (pore size \> 75µm) monofilament polypropylene mesh (Intracorp®, Venkuri, www.venkuri.com.br) was used in the onlay position, to reinforce the repair. The mesh was fixed with multiple absorbable Vicryl® sutures, placed over the borders of the mesh, in the midline and along the relaxing incisions. The remaining dead space between the mesh and the underlying tissue was cleared entirely with interrupted sutures. The operative field was irrigated with 0,9% saline, and the subcutaneous was drained with suction drains. The scars and the exceeding skin flaps were resected. We did not use irrigation with antibiotics solution. The subcutaneous tissue and the skin were closed with interrupted sutures. Fluids and samples of the explanted mesh were sent to cultures and microbiological analysis. The same technique of repair was used in the CC group. The size of the defect was measured, and the extension of the anterior abdominal wall dissection was estimated. A bilateral relaxing incision along the anterior rectus sheath was used routinely in this group, to allow a tensionless closure of the midline. Outcomes parameters The primary outcomes variables were the presence of any surgical site occurrences (SSO) or surgical site infection (SSI) during the first 30 days after the operation, and the development of hernia recurrence or the recurrence of mesh infection during a 36-month follow-up period. Suspected recurrences of a hernia or infection were determined by physical examination and CT scan imaging. Non-surgical complications, other operations, and deaths were registered during the follow-up period. Statistical Analysis The chi-square test was conducted to verify the association between categorical variables in contingency tables and the Fisher exact test was adopted in 2x2 tables whenever at least one expected frequency was less than 5. The U-test was used for verifying the association between continuous data and group with two categories, and when normal distribution was observed the Student t-test was performed. The 5% level of significance was considered for all statistical tests. Statistical computer Stata software version 10.0 (StataCorp, College Station, TX) was used for conducting all statistical analysis.

Interventions

The repair of abdominal wall defects with polypropylene mesh

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

A study group submitted to abdominal wall repair with synthetic mesh in the contaminated/infected setting compared to a control group submitted to abdominal wall repair with synthetic mesh in the clean setting.

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Inclusion Criterion \- the presence of an active chronic mesh infection

Exclusion criteria

* giant ventral hernias with a volume ratio higher than 25% and loss of domicile * patients on immunosuppressive therapy or using corticosteroids * patients with hepatic cirrhosis and portal hypertension * Chron´s disease * acute postoperative mesh infection * chronic mesh infections following inguinal hernia repair * emergency operations.

Design outcomes

Primary

MeasureTime frameDescription
Surgical site occurrence30 daysany surgical infection, wound breakdown, soft tissue ischemia, seroma and hematoma formation

Secondary

MeasureTime frameDescription
Surgical Site infection30 daysan infection occurring in the part of the body where the surgery took place and further defined as superficial, deep, and organ space
Surgical site occurrence requiring procedural intervention30 daysany wound event requiring opening of the wound, wound debridement, suture excision, percutaneous drainage, hematoma evacuation, or mesh removal
Ventral hernia recurrence36 monthsa recurrence of ventral hernia
Mesh infection recurrence36 monthsa recurrence of mesh infection

Other

MeasureTime frameDescription
Microbiology of mesh infection30 daysa study of the microorganisms causing chronic mesh infection

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026